Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Distal deletion 9p
Distal deletion 9p
Distal deletion 9p
Synonyms: Distal monosomy 9p, Monosomy 9pter, Telomeric deletion 9p
Synonyms: Distal monosomy 9p, Monosomy 9pter, Telomeric deletion 9p
Synonyms: Distal monosomy 9p, Monosomy 9pter, Telomeric deletion 9p
Drug discovery
4
papers
On emerging therapies
Rare developmental defect during embryogenesis
Distal deletion 9p
Overview
Distal deletion 9p syndrome (OMIM: 158170), also known as Alfi syndrome, is a rare chromosomal disorder caused by partial deletion of the short arm of chromosome 9 (9p24.3-pter). It is characterized by intellectual disability, craniofacial dysmorphism (e.g., trigonocephaly, upslanting palpebral fissures), genitourinary anomalies (e.g., hypospadias, gonadal dysgenesis), and skeletal abnormalities. Cardiac defects (35–50%) and increased gonadoblastoma risk are notable complications [1][4][6][12].
Burden
Clinical burden: Lifelong intellectual disability (mean IQ ~48), speech delays, and hypotonia; ~20% require cardiac surgery [4][11][12].
Psychosocial burden: High care needs due to developmental delays, behavioral challenges, and recurrent infections [11][12].
Economic burden: Frequent hospitalizations, surgical interventions, and long-term therapies strain families and healthcare systems [6][12].
Therapies
Multidisciplinary care: Surgical correction of craniosynostosis, cardiac defects, and hernias; neurodevelopmental support (speech/occupational therapy) [3][6][11].
Monitoring: Regular cardiac and endocrine evaluations; surveillance for gonadoblastoma in 46,XY individuals [1][6][12].
Anesthetic precautions: Anticipation of difficult airways and tailored perioperative management [3][12].
Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare gynecological and obstetric diseases, rare urogenital diseases
Research Papers
4 drug discovery papers about Distal deletion 9p. Recent publications:
4 drug discovery papers about Distal deletion 9p. Recent publications:
categories:
Small molecules
gene therapies
2025-04-29 | Congenital hyperinsulinemic hypoglycaemia in an infant with 9p deletion syndrome
To the editor, Constitutional monosomy of part of the short arm of chromosome 9 (chromosome 9p deletion syndrome, OMIM #158170) results in a rare, complex syndromic condition characterized by developmental delay, craniofacial dysmorphism, and multiple congenital anomalies [1][2][3].Variability in clinical features may be due to differences in the extent of deletion and haploinsufficiency of specific genes.The genotype-phenotype correlation is unclear due to frequent additional chromosomal rearrangements and inconsistent molecular characterization.Gene disruption within the affected region may reveal recessive traits, contributing to the complex presentation [2].Congenital hyperinsulinism (CHI) occurs in less than 10% of patients with chromosome 9p deletion syndrome.Its course can be variable, it may require several years of treatment, and the genetic mechanism underlying dysregulated insulin secretion remains unidentified [4][5][6].Distal duplication of 14q is rare and is characterized by variable clinical features, including developmental delay, growth retardation, low birth weight, hypotonia, short stature, microcephaly, facial dysmorphism, spasticity, and hyperreflexia; brain, cardiac, digital, and skeletal abnormalities are also likely [7][8][9].We present a rare case of CHI in an infant with a karyotype of 46,XX,der(9)t(9p;14q) (p23;q32.2).An 8-month-old female patient was referred to our department for hypoglycemia evaluation.She was the first child born to a 40-year-old mother via cesarean section at 41 weeks of gestation.Her mother had no history of gestational diabetes or other medical conditions, nor did she take any medications during pregnancy.There was no history of diabetes in her father or in three generations of her family.The patient's birth weight, length, and head circumference were 2,990 g (10th-25th percentile), 48 cm (10th-25th percentile), and 35 cm (25th percentile), respectively.After birth, she was admitted to the neonatal intensive care unit because of respiratory failure, hypotonia, cleft palate, and dysmorphic features.Intermittent nasal positive-pressure ventilation was administered immediately after admission because of tachypnea and mild chest retraction.On the first day of life (DOL 1), initial blood glucose level was less than 20 mg/dL.She developed pneumomediastinum with persistent pulmonary hypertension (PPHN).Continuous glucose infusion (glucose infusion rate [GIR], 11 mg/kg/min) dopamine, dobutamine, milrinone, inhaled prostacyclin for PPHN, and intravenous hydrocortisone (5 mg/kg/day) were administered due to PPHN and the possibility of relative adrenal insufficiency.On DOL 2, glucose level reached 29 mg/dL, and a detectable serum insulin level of 93.6 U/mL, undetectable ketone bodies (0.3 mmol/L), and a normal ammonia level of 51 mol/L were observed.Echocardiography revealed a mild atrial septum defect, nearly closing the patent ductus arteriosus, and mild septal hypertrophy.Brain magnetic resonance imaging showed a thinning of the corpus callosum, and small T1 hyperintensity in the left frontal deep white matter, suggesting a small hemorrhagic lesion.Karyotyping revealed 46,XX,add(9)(p23).Chromosome microarray analysis (Affymetrix CytoScan 750K Array, Thermo Fisher Scientific, Santa Clara, CA, USA) with human genomic reference sequence GRCh37/hg19 revealed an approximately 10-Mbp deletion at 9p24.3p23, classified as a pathogenic copy number variant (CNV), an 860-kbp duplication at 14q32.2, considered a variant of uncertain significance, and a 9.8-Mbp duplication at 14q32.2q32.33,also classified as a pathogenic CNV (Fig. 1).The patient's karyotype was considered
1997-04-01 | Impaired male sex development in an infant with molecularly defined partial 9p monosomy: implication for a testis forming gene(s) on 9p.
This paper describes a genetically male infant with impaired male sex development and partial 9p monosomy. The external genitalia were ambiguous with microphallus (penile length at birth 10 mm, mean age matched normal length 29 mm (SD 5)), hypospadias, and hypoplastic scrotum. The tests were undescended and severely hypoplastic (testis size at 12 months of age, right 8 x 5 x 4 mm and left 4 x 3 x 2 mm; mean age matched normal size, length 18 mm (SD 2), width 11 mm (SD 1). Cytogenetic studies showed a 46,XY,del(9)(p23) karyotype in all the 30 peripheral lymphocytes and 20 skin fibroblasts examined. Microsatellite analysis for a total of 13 loci assigned to the 9p22-24 region showed that the deleted chromosome 9 was of paternal origin and was missing a region distal to D9S168. Southern blot analysis for D9S47 also confirmed the 9p deletion. The sequence of SRY was normal. The results provide further support for the previously proposed hypothesis that a gene(s) for testis formation is present on the distal part of 9p and indicate in molecular terms that the putative testis forming gene(s) resides in the region distal to D9S168.
small molecules
2026-06-08 | Primary Ovarian Insufficiency in an Adult Female with 9p Distal Deletion Syndrome
Primary ovarian insufficiency (POI) can be a devastating diagnosis with significant psychological stress and life-long health problems including cardiovascular disease, osteoporosis, and diminished life expectancy. We present a case of a 26-year-old adult female (XX) with distal deletion of chromosome 9p who presented with secondary amenorrhea for five years. She had typical dysmorphic features of 9p deletion syndrome. She required a G-tube for nutritional support and was non communicative. Her BMI was 16 and initial consideration was hypothalamic amenorrhea. Her FSH was 25mIU/mL, estradiol was 6 pg/mL, total testosterone was 11 ng/dL, and prolactin was 11 ng/mL consistent with primary ovarian insufficiency (POI). This is now the second reported case of an adult XX individual and distal 9p deletion to present with primary ovarian insufficiency. The DMRT1 gene loci is located on the distal portion of chromosome 9p. This is further evidence that abnormalities (hemizygosity) of DMRT1 may be associated with POI and possibly causative. Adult patients with distal 9p deletion should be screened for POI and, when present, hormone replacement should be considered.
2025-10-22 | Abstract B027: TNG961: A selective oral molecular glue degrader of HBS1L inducing tumor regression in naïve and PRMT5i-refractory FOCAD-deleted models
Abstract Chromosomal deletion of tumor suppressor genes can lead to collateral loss of nearby genes, creating therapeutic opportunities for synthetic lethal targeting. One example is the frequent co-deletion of MTAP with CDKN2A/B on chromosome 9p, which creates a dependency on PRMT5 for cell survival. Located telomeric to CDKN2A and MTAP is FOCAD, a gene encoding a protein essential for stabilizing the SKI complex. The SKI complex is responsible for degrading aberrant mRNAs, thereby maintaining mRNA homeostasis. Loss of FOCAD disrupts SKI complex function, resulting in ribosome stalling on aberrant mRNA transcripts. These stalled ribosomes are dependent on the HBS1L/PELO complex for rescue and recycling, establishing a synthetic lethal interaction between HBS1L/PELO and FOCAD loss. TNG961 is a first-in-class molecular glue that targets HBS1L for degradation, representing a novel therapeutic strategy for FOCAD-deleted tumors. In vitro, TNG961 treatment leads to a dose-dependent decrease in HBS1L protein levels, which in turn destabilizes the portion of PELO involved in ribosome rescue. TNG961 displays proteome-wide selectivity for HBS1L, with no change in SALL4 protein level as determined by western blot. TNG961-induced HBS1L degradation and PELO destabilization can both be rescued by inactivation of CRBN confirming mechanism, which is further supported by cryoEM data. In engineered HiBiT knock-in cells, treatment with TNG961 induces maximal HBS1L degradation within 4 hours, without affecting GSPT1 protein levels. This selective degradation translates to potent growth inhibition in FOCAD-deleted cells, with ∼100-fold selectivity compared to FOCAD-proficient cells across 5 isogenic pairs. This selective vulnerability is preserved in a large cell line panel of over 90 models. Finally, oral administration of TNG961 induces dose-dependent degradation of HBS1L and subsequent destabilization of PELO protein in FOCAD-deleted xenograft models, resulting in tumor stasis or regression across multiple lineages. Notably, TNG961 remains effective in a pancreatic model that has become refractory to PRMT5 inhibitor treatment, supporting its potential utility in PRMT5i-resistant settings. TNG961 has been nominated as a development candidate and is currently in IND-enabling studies. Citation Format: Katherine Lazarides, Minjie Zhang, Frank J. Bruzzese, Douglas A. Whittington, Charlotte B. Pratt, Lauren Catherine M. Martires, John P. Maxwell, Alice Tsai, Colin Liang, Patrick McCarren, Yong Liu, John Zhang, Matthew R. Tonini, Margaret A. Wyman, Xinyuan Wu, Jannik N. Andersen, Hilary E. Nicholson. TNG961: A selective oral molecular glue degrader of HBS1L inducing tumor regression in naïve and PRMT5i-refractory FOCAD-deleted models [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2025 Oct 22-26; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2025;24(10 Suppl):Abstract nr B027.
gene therapies
2025-04-29 | Congenital hyperinsulinemic hypoglycaemia in an infant with 9p deletion syndrome
To the editor, Constitutional monosomy of part of the short arm of chromosome 9 (chromosome 9p deletion syndrome, OMIM #158170) results in a rare, complex syndromic condition characterized by developmental delay, craniofacial dysmorphism, and multiple congenital anomalies [1][2][3].Variability in clinical features may be due to differences in the extent of deletion and haploinsufficiency of specific genes.The genotype-phenotype correlation is unclear due to frequent additional chromosomal rearrangements and inconsistent molecular characterization.Gene disruption within the affected region may reveal recessive traits, contributing to the complex presentation [2].Congenital hyperinsulinism (CHI) occurs in less than 10% of patients with chromosome 9p deletion syndrome.Its course can be variable, it may require several years of treatment, and the genetic mechanism underlying dysregulated insulin secretion remains unidentified [4][5][6].Distal duplication of 14q is rare and is characterized by variable clinical features, including developmental delay, growth retardation, low birth weight, hypotonia, short stature, microcephaly, facial dysmorphism, spasticity, and hyperreflexia; brain, cardiac, digital, and skeletal abnormalities are also likely [7][8][9].We present a rare case of CHI in an infant with a karyotype of 46,XX,der(9)t(9p;14q) (p23;q32.2).An 8-month-old female patient was referred to our department for hypoglycemia evaluation.She was the first child born to a 40-year-old mother via cesarean section at 41 weeks of gestation.Her mother had no history of gestational diabetes or other medical conditions, nor did she take any medications during pregnancy.There was no history of diabetes in her father or in three generations of her family.The patient's birth weight, length, and head circumference were 2,990 g (10th-25th percentile), 48 cm (10th-25th percentile), and 35 cm (25th percentile), respectively.After birth, she was admitted to the neonatal intensive care unit because of respiratory failure, hypotonia, cleft palate, and dysmorphic features.Intermittent nasal positive-pressure ventilation was administered immediately after admission because of tachypnea and mild chest retraction.On the first day of life (DOL 1), initial blood glucose level was less than 20 mg/dL.She developed pneumomediastinum with persistent pulmonary hypertension (PPHN).Continuous glucose infusion (glucose infusion rate [GIR], 11 mg/kg/min) dopamine, dobutamine, milrinone, inhaled prostacyclin for PPHN, and intravenous hydrocortisone (5 mg/kg/day) were administered due to PPHN and the possibility of relative adrenal insufficiency.On DOL 2, glucose level reached 29 mg/dL, and a detectable serum insulin level of 93.6 U/mL, undetectable ketone bodies (0.3 mmol/L), and a normal ammonia level of 51 mol/L were observed.Echocardiography revealed a mild atrial septum defect, nearly closing the patent ductus arteriosus, and mild septal hypertrophy.Brain magnetic resonance imaging showed a thinning of the corpus callosum, and small T1 hyperintensity in the left frontal deep white matter, suggesting a small hemorrhagic lesion.Karyotyping revealed 46,XX,add(9)(p23).Chromosome microarray analysis (Affymetrix CytoScan 750K Array, Thermo Fisher Scientific, Santa Clara, CA, USA) with human genomic reference sequence GRCh37/hg19 revealed an approximately 10-Mbp deletion at 9p24.3p23, classified as a pathogenic copy number variant (CNV), an 860-kbp duplication at 14q32.2, considered a variant of uncertain significance, and a 9.8-Mbp duplication at 14q32.2q32.33,also classified as a pathogenic CNV (Fig. 1).The patient's karyotype was considered
1997-04-01 | Impaired male sex development in an infant with molecularly defined partial 9p monosomy: implication for a testis forming gene(s) on 9p.
This paper describes a genetically male infant with impaired male sex development and partial 9p monosomy. The external genitalia were ambiguous with microphallus (penile length at birth 10 mm, mean age matched normal length 29 mm (SD 5)), hypospadias, and hypoplastic scrotum. The tests were undescended and severely hypoplastic (testis size at 12 months of age, right 8 x 5 x 4 mm and left 4 x 3 x 2 mm; mean age matched normal size, length 18 mm (SD 2), width 11 mm (SD 1). Cytogenetic studies showed a 46,XY,del(9)(p23) karyotype in all the 30 peripheral lymphocytes and 20 skin fibroblasts examined. Microsatellite analysis for a total of 13 loci assigned to the 9p22-24 region showed that the deleted chromosome 9 was of paternal origin and was missing a region distal to D9S168. Southern blot analysis for D9S47 also confirmed the 9p deletion. The sequence of SRY was normal. The results provide further support for the previously proposed hypothesis that a gene(s) for testis formation is present on the distal part of 9p and indicate in molecular terms that the putative testis forming gene(s) resides in the region distal to D9S168.
small molecules
2026-06-08 | Primary Ovarian Insufficiency in an Adult Female with 9p Distal Deletion Syndrome
Primary ovarian insufficiency (POI) can be a devastating diagnosis with significant psychological stress and life-long health problems including cardiovascular disease, osteoporosis, and diminished life expectancy. We present a case of a 26-year-old adult female (XX) with distal deletion of chromosome 9p who presented with secondary amenorrhea for five years. She had typical dysmorphic features of 9p deletion syndrome. She required a G-tube for nutritional support and was non communicative. Her BMI was 16 and initial consideration was hypothalamic amenorrhea. Her FSH was 25mIU/mL, estradiol was 6 pg/mL, total testosterone was 11 ng/dL, and prolactin was 11 ng/mL consistent with primary ovarian insufficiency (POI). This is now the second reported case of an adult XX individual and distal 9p deletion to present with primary ovarian insufficiency. The DMRT1 gene loci is located on the distal portion of chromosome 9p. This is further evidence that abnormalities (hemizygosity) of DMRT1 may be associated with POI and possibly causative. Adult patients with distal 9p deletion should be screened for POI and, when present, hormone replacement should be considered.
2025-10-22 | Abstract B027: TNG961: A selective oral molecular glue degrader of HBS1L inducing tumor regression in naïve and PRMT5i-refractory FOCAD-deleted models
Abstract Chromosomal deletion of tumor suppressor genes can lead to collateral loss of nearby genes, creating therapeutic opportunities for synthetic lethal targeting. One example is the frequent co-deletion of MTAP with CDKN2A/B on chromosome 9p, which creates a dependency on PRMT5 for cell survival. Located telomeric to CDKN2A and MTAP is FOCAD, a gene encoding a protein essential for stabilizing the SKI complex. The SKI complex is responsible for degrading aberrant mRNAs, thereby maintaining mRNA homeostasis. Loss of FOCAD disrupts SKI complex function, resulting in ribosome stalling on aberrant mRNA transcripts. These stalled ribosomes are dependent on the HBS1L/PELO complex for rescue and recycling, establishing a synthetic lethal interaction between HBS1L/PELO and FOCAD loss. TNG961 is a first-in-class molecular glue that targets HBS1L for degradation, representing a novel therapeutic strategy for FOCAD-deleted tumors. In vitro, TNG961 treatment leads to a dose-dependent decrease in HBS1L protein levels, which in turn destabilizes the portion of PELO involved in ribosome rescue. TNG961 displays proteome-wide selectivity for HBS1L, with no change in SALL4 protein level as determined by western blot. TNG961-induced HBS1L degradation and PELO destabilization can both be rescued by inactivation of CRBN confirming mechanism, which is further supported by cryoEM data. In engineered HiBiT knock-in cells, treatment with TNG961 induces maximal HBS1L degradation within 4 hours, without affecting GSPT1 protein levels. This selective degradation translates to potent growth inhibition in FOCAD-deleted cells, with ∼100-fold selectivity compared to FOCAD-proficient cells across 5 isogenic pairs. This selective vulnerability is preserved in a large cell line panel of over 90 models. Finally, oral administration of TNG961 induces dose-dependent degradation of HBS1L and subsequent destabilization of PELO protein in FOCAD-deleted xenograft models, resulting in tumor stasis or regression across multiple lineages. Notably, TNG961 remains effective in a pancreatic model that has become refractory to PRMT5 inhibitor treatment, supporting its potential utility in PRMT5i-resistant settings. TNG961 has been nominated as a development candidate and is currently in IND-enabling studies. Citation Format: Katherine Lazarides, Minjie Zhang, Frank J. Bruzzese, Douglas A. Whittington, Charlotte B. Pratt, Lauren Catherine M. Martires, John P. Maxwell, Alice Tsai, Colin Liang, Patrick McCarren, Yong Liu, John Zhang, Matthew R. Tonini, Margaret A. Wyman, Xinyuan Wu, Jannik N. Andersen, Hilary E. Nicholson. TNG961: A selective oral molecular glue degrader of HBS1L inducing tumor regression in naïve and PRMT5i-refractory FOCAD-deleted models [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2025 Oct 22-26; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2025;24(10 Suppl):Abstract nr B027.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.